• 1. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 2. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 3. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 4. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 5. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126

Introduction to 4-Cyanopyrimidine-2-carboxylic acid (CAS No. 1956376-20-7)

4-Cyanopyrimidine-2-carboxylic acid, identified by the Chemical Abstracts Service Number (CAS No.) 1956376-20-7, is a significant compound in the realm of organic chemistry and pharmaceutical research. This heterocyclic organic compound belongs to the pyrimidine family, characterized by a six-membered ring containing two nitrogen atoms. The presence of a cyano group at the 4-position and a carboxylic acid moiety at the 2-position imparts unique chemical properties, making it a valuable intermediate in the synthesis of various biologically active molecules.

The structure of 4-cyanopyrimidine-2-carboxylic acid lends itself to diverse chemical modifications, which are exploited in medicinal chemistry for the development of novel therapeutic agents. Its pyrimidine core is a common scaffold in many pharmacologically relevant compounds, particularly those targeting nucleic acid metabolism and enzyme inhibition. The cyano group can participate in further functionalization, such as reduction to an amine or conversion to a carboxamide, while the carboxylic acid can be esterified or amidated to enhance solubility and bioavailability.

In recent years, 4-cyanopyrimidine-2-carboxylic acid has garnered attention in the design of inhibitors for enzymes involved in cancer pathways. Pyrimidine derivatives are well-documented for their ability to interact with biological targets such as kinases and polymerases. For instance, studies have explored its potential as a precursor in synthesizing small-molecule inhibitors that disrupt tumor growth by modulating key signaling cascades. The compound’s ability to mimic natural pyrimidines makes it a promising candidate for developing antiviral and anticancer drugs.

Moreover, the pharmaceutical industry has leveraged 4-cyanopyrimidine-2-carboxylic acid in the development of antibiotics and antifungal agents. The structural features of this compound allow for selective binding to bacterial enzymes, inhibiting their growth without harming host cells. Researchers have reported modifications of its core structure to enhance potency and reduce side effects, underscoring its versatility as a building block in drug discovery.

The synthetic pathways for 4-cyanopyrimidine-2-carboxylic acid are also of great interest due to their potential scalability and efficiency. Modern synthetic methods often employ catalytic processes that minimize waste and improve yields, aligning with green chemistry principles. Advances in flow chemistry have enabled the production of this compound in controlled environments, facilitating its use in large-scale applications without compromising purity or yield.

From a biochemical perspective, 4-cyanopyrimidine-2-carboxylic acid plays a role in modulating metabolic pathways. Its derivatives have been investigated for their effects on mitochondrial function and DNA repair mechanisms. By interacting with enzymes such as cytochrome P450 oxidases, these compounds can influence drug metabolism and efficacy, providing insights into potential therapeutic applications for metabolic disorders.

The regulatory landscape for compounds like 4-cyanopyrimidine-2-carboxylic acid is stringent but well-established, ensuring that their development and use adhere to safety and efficacy standards. Manufacturers must navigate complex guidelines set forth by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to bring new derivatives to market. This rigorous oversight underscores the importance of thorough research before clinical translation.

Future research directions may focus on expanding the chemical space around 4-cyanopyrimidine-2-carboxylic acid through computational modeling and high-throughput screening. Machine learning algorithms can predict novel derivatives with enhanced biological activity, accelerating the drug discovery pipeline. Collaborative efforts between academia and industry are essential to translate these findings into tangible therapeutic benefits for patients worldwide.

In conclusion, 4-cyanopyrimidine-2-carboxylic acid (CAS No. 1956376-20-7) represents a cornerstone in modern medicinal chemistry. Its unique structural features enable diverse applications across multiple therapeutic areas, from oncology to infectious diseases. As research continues to uncover new synthetic routes and biological functions, this compound will remain at the forefront of pharmaceutical innovation.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)